Vikas Sinha Sells 18,331 Shares of AlloVir, Inc. (NASDAQ:ALVR) Stock

AlloVir, Inc. (NASDAQ:ALVRGet Free Report) insider Vikas Sinha sold 18,331 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $0.67, for a total transaction of $12,281.77. Following the sale, the insider now owns 1,145,252 shares of the company’s stock, valued at approximately $767,318.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Vikas Sinha also recently made the following trade(s):

  • On Tuesday, January 23rd, Vikas Sinha sold 3,205 shares of AlloVir stock. The stock was sold at an average price of $0.67, for a total transaction of $2,147.35.
  • On Thursday, January 4th, Vikas Sinha sold 961 shares of AlloVir stock. The stock was sold at an average price of $0.64, for a total transaction of $615.04.
  • On Friday, November 17th, Vikas Sinha sold 2,490 shares of AlloVir stock. The stock was sold at an average price of $1.63, for a total transaction of $4,058.70.

AlloVir Trading Down 2.6 %

NASDAQ:ALVR opened at $0.67 on Thursday. The firm has a 50-day moving average price of $1.18 and a two-hundred day moving average price of $1.90. AlloVir, Inc. has a twelve month low of $0.62 and a twelve month high of $7.24. The company has a market capitalization of $76.74 million, a P/E ratio of -0.40 and a beta of 0.84.

Institutional Investors Weigh In On AlloVir

Several hedge funds have recently modified their holdings of ALVR. Swiss National Bank boosted its stake in shares of AlloVir by 7.5% during the 1st quarter. Swiss National Bank now owns 84,800 shares of the company’s stock worth $572,000 after purchasing an additional 5,900 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of AlloVir by 27.7% during the 1st quarter. JPMorgan Chase & Co. now owns 763,908 shares of the company’s stock worth $5,157,000 after purchasing an additional 165,711 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of AlloVir by 51.5% in the first quarter. MetLife Investment Management LLC now owns 18,052 shares of the company’s stock worth $122,000 after acquiring an additional 6,136 shares during the last quarter. BlackRock Inc. grew its holdings in AlloVir by 2.9% during the first quarter. BlackRock Inc. now owns 2,230,919 shares of the company’s stock valued at $15,059,000 after purchasing an additional 62,747 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in AlloVir by 43.5% during the first quarter. Dimensional Fund Advisors LP now owns 70,387 shares of the company’s stock valued at $476,000 after purchasing an additional 21,337 shares during the last quarter. 47.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALVR has been the subject of a number of analyst reports. Piper Sandler downgraded shares of AlloVir from an “overweight” rating to a “neutral” rating in a research report on Friday, December 22nd. SVB Leerink downgraded shares of AlloVir from an “outperform” rating to a “market perform” rating in a report on Friday, December 22nd. JPMorgan Chase & Co. downgraded shares of AlloVir from an “overweight” rating to an “underweight” rating in a report on Friday, December 22nd. Bank of America downgraded shares of AlloVir from a “buy” rating to an “underperform” rating in a report on Tuesday, December 26th. Finally, Leerink Partnrs downgraded shares of AlloVir from an “outperform” rating to a “market perform” rating in a report on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $18.67.

Check Out Our Latest Stock Analysis on AlloVir

About AlloVir

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Further Reading

Insider Buying and Selling by Quarter for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.